Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

PF-06821497 Behandling af recidiverende/refraktær SCLC, kastrationsresistent prostatakræft og follikulært lymfom

14. oktober 2026 opdateret af: Pfizer

ET FASE I DOSESEKALATION OG UDVIDET KOHORTSTUDIE AF PF-06821497 TIL BEHANDLING AF VOKSNE PATIENTER MED RELIPSAT/REFRAKTÆR Småcellet lungecancer (SCLC), KASTRATIONSRESISTENT PROSTATACANCER (CRMPOLLIPC)

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.

Part 3, which is open for enrollment is seeking men who:

  • have Castration Resistant Prostate Cancer (CRPC) and
  • have previously received treatment for CRPC and have progressed from the last treatment

All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).

In the assessment phase:

  • participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
  • participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
  • participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.

After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.

The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.

Studieoversigt

Detaljeret beskrivelse

This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).

Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

453

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Haskovo, Bulgarien, 6300
        • Afsluttet
        • Specialized Hospital for Active Treatment of Oncology - Haskovo
    • Arizona
      • Tucson, Arizona, Forenede Stater, 85719
        • Aktiv, ikke rekrutterende
        • Banner-University Medical Center Tucson
      • Tucson, Arizona, Forenede Stater, 85719
        • Aktiv, ikke rekrutterende
        • The University of Arizona Cancer Center-North Campus
      • Tucson, Arizona, Forenede Stater, 85724
        • Aktiv, ikke rekrutterende
        • The University of Arizona Cancer Center
      • Tucson, Arizona, Forenede Stater, 85741
        • Afsluttet
        • Arizona Urology Specialists, PLLC
    • California
      • Anaheim, California, Forenede Stater, 92801
        • Aktiv, ikke rekrutterende
        • Pacific Cancer Medical Center INC
      • Duarte, California, Forenede Stater, 91010
        • Aktiv, ikke rekrutterende
        • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
      • Duarte, California, Forenede Stater, 91010
        • Aktiv, ikke rekrutterende
        • City of Hope Investigational Drug Services (IDS)
    • Connecticut
      • Norwalk, Connecticut, Forenede Stater, 06856
        • Aktiv, ikke rekrutterende
        • Norwalk Hospital
    • Kansas
      • Fairway, Kansas, Forenede Stater, 66205
        • Aktiv, ikke rekrutterende
        • The University of Kansas Cancer Center, Investigational Drug Services
      • Fairway, Kansas, Forenede Stater, 66205
        • Aktiv, ikke rekrutterende
        • The University of Kansas Clinical Research Center
      • Kansas City, Kansas, Forenede Stater, 66160
        • Aktiv, ikke rekrutterende
        • The University of Kansas Hospital
      • Kansas City, Kansas, Forenede Stater, 66160
        • Aktiv, ikke rekrutterende
        • The University of Kansas Medical Center Medical Office Building
      • Overland Park, Kansas, Forenede Stater, 66211
        • Aktiv, ikke rekrutterende
        • The University of Kansas Cancer Center - Indian Creek Campus
      • Westwood, Kansas, Forenede Stater, 66205
        • Aktiv, ikke rekrutterende
        • The University of Kansas Cancer Center
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40202
        • Aktiv, ikke rekrutterende
        • Norton Cancer Institute, Norton Healthcare Pavilion
      • Louisville, Kentucky, Forenede Stater, 40202
        • Aktiv, ikke rekrutterende
        • Norton Hospital
      • Louisville, Kentucky, Forenede Stater, 40202
        • Aktiv, ikke rekrutterende
        • Norton Cancer Institute - Downtown
    • Maryland
      • Rockville, Maryland, Forenede Stater, 20850
        • Afsluttet
        • Maryland Oncology Hematology, P.A.
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Aktiv, ikke rekrutterende
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, Forenede Stater, 02115
        • Aktiv, ikke rekrutterende
        • Brigham and Women's Hospital
      • Newton, Massachusetts, Forenede Stater, 02459
        • Aktiv, ikke rekrutterende
        • Dana Farber Cancer Institute- Chestnut Hill
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68130
        • Rekruttering
        • Oncology Hematology West, PC dba Nebraska Cancer Specialists
    • New Jersey
      • Hackensack, New Jersey, Forenede Stater, 07601
        • Aktiv, ikke rekrutterende
        • Hackensack University Medical Center
      • Hackensack, New Jersey, Forenede Stater, 07601
        • Aktiv, ikke rekrutterende
        • John Theurer Cancer Center at Hackensack University Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Rekruttering
        • OU Health University of Oklahoma Medical Center
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Rekruttering
        • Stephenson Cancer Center (chemo location)
    • South Carolina
      • Myrtle Beach, South Carolina, Forenede Stater, 29572
        • Rekruttering
        • Carolina Urologic Research Center
      • Myrtle Beach, South Carolina, Forenede Stater, 29572
        • Rekruttering
        • Parkway Surgery Center
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • Sarah Cannon Research Institute - Pharmacy
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • SCRI Oncology Partners
    • Texas
      • Austin, Texas, Forenede Stater, 78705
        • Afsluttet
        • Texas Oncology - Austin Midtown
      • Dallas, Texas, Forenede Stater, 75390
        • Aktiv, ikke rekrutterende
        • UT Southwestern Medical Center
      • Dallas, Texas, Forenede Stater, 75390
        • Aktiv, ikke rekrutterende
        • University of Texas Southwestern Medical Center - Simmons Cancer Center
      • Dallas, Texas, Forenede Stater, 75390
        • Aktiv, ikke rekrutterende
        • UT Southwestern University Hospital - William P. Clements, Jr
      • Dallas, Texas, Forenede Stater, 75390
        • Aktiv, ikke rekrutterende
        • UT Southwestern University Hospital - Zale Lipshy
      • Irving, Texas, Forenede Stater, 75063
        • Afsluttet
        • US Oncology Investigational Product Center (IPC)
      • Irving, Texas, Forenede Stater, 75063
        • Afsluttet
        • US Oncology Investigational Products Center
      • Irving, Texas, Forenede Stater, 75039
        • Rekruttering
        • NEXT Dallas
      • San Antonio, Texas, Forenede Stater, 78229
        • Rekruttering
        • NEXT Oncology
      • San Antonio, Texas, Forenede Stater, 78240
        • Aktiv, ikke rekrutterende
        • NEXT Oncology
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
        • Aktiv, ikke rekrutterende
        • Virginia Cancer Specialists, PC
    • Washington
      • Port Angeles, Washington, Forenede Stater, 98362
        • Aktiv, ikke rekrutterende
        • Olympic Medical Center
      • Poulsbo, Washington, Forenede Stater, 98370
        • Aktiv, ikke rekrutterende
        • Fred Hutchinson Cancer Center Alliance Peninsula
      • Seattle, Washington, Forenede Stater, 98109
        • Aktiv, ikke rekrutterende
        • Fred Hutchinson Cancer Center
      • Seattle, Washington, Forenede Stater, 98109
        • Aktiv, ikke rekrutterende
        • University of Washington Medical Center
    • Chiba
      • Kashiwa, Chiba, Japan, 277-8577
        • Aktiv, ikke rekrutterende
        • National Cancer Center Hospital East
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510120
        • Aktiv, ikke rekrutterende
        • The First Affiliated Hospital of Guangzhou Medical University
    • Hunan
      • Changsha, Hunan, Kina, 410013
        • Aktiv, ikke rekrutterende
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210009
        • Aktiv, ikke rekrutterende
        • Zhongda Hospital Southeast University
      • Nanjing, Jiangsu, Kina, 210008
        • Aktiv, ikke rekrutterende
        • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Rekruttering
        • West China Hospital, Sichuan University
    • Zhejiang
      • Wenzhou, Zhejiang, Kina, 325000
        • Aktiv, ikke rekrutterende
        • The First Affiliated Hospital of Wenzhou Medical University
      • Bydgoszcz, Polen, 85-048
        • Ikke rekrutterer endnu
        • In-Vivo Sp. z o.o. In-vivo Bydgoszcz
      • Koszalin, Polen, 75-581
        • Aktiv, ikke rekrutterende
        • Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
      • Krakow, Polen, 30-348
        • Rekruttering
        • Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
      • Rzeszów, Polen, 35-326
        • Aktiv, ikke rekrutterende
        • Centrum Medyczne MEDYK
      • Warsaw, Polen, 02-781
        • Aktiv, ikke rekrutterende
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
      • Moscow, Rusland, 117186
        • Aktiv, ikke rekrutterende
        • LLC "Neyro-klinika"
      • Moscow, Rusland, 125284
        • Afsluttet
        • Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
      • Moscow, Rusland, 129301
        • Afsluttet
        • SBHI of Moscow City Clinical Hospital
      • Omsk, Rusland, 644013
        • Afsluttet
        • Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
      • Saint Petersburg, Rusland, 197341
        • Afsluttet
        • Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
      • Saint Petersburg, Rusland, 197758
        • Afsluttet
        • Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
      • Saint Petersburg, Rusland, 198255
        • Afsluttet
        • Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
      • Yaroslavl, Rusland, 150054
        • Afsluttet
        • State Budgetary Healthcare Institution of the Yaroslavl Region
    • Sankt-Peterburg
      • Pushkin, Sankt-Peterburg, Rusland, 196603
        • Aktiv, ikke rekrutterende
        • Private Medical Institution "Euromedservice"
      • Barcelona, Spanien, 08035
        • Rekruttering
        • Hospital Universitari Vall d'Hebron
      • Barcelona, Spanien, 08036
        • Rekruttering
        • Hospital Clinic de Barcelona
      • Barcelona, Spanien, 08023
        • Rekruttering
        • Hospital Quironsalud Barcelona
      • Madrid, Spanien, 28034
        • Rekruttering
        • Hospital Universitario Ramon y Cajal
      • Madrid, Spanien, 28040
        • Rekruttering
        • Hospital Clinico San Carlos
      • Madrid, Spanien, 28050
        • Rekruttering
        • Hospital Universitario HM Sanchinarro
      • Madrid, Spanien, 28040
        • Rekruttering
        • H.U. Fundación Jiménez Díaz
      • Madrid, Spanien, 28041
        • Rekruttering
        • Hospital Universitario 12 De Octubre
      • Málaga, Spanien, 29010
        • Rekruttering
        • Hospital Universitario Virgen de la Victoria
      • Valencia, Spanien, 46026
        • Aktiv, ikke rekrutterende
        • Hospital Universitari i Politecnic La Fe
    • Barecelona
      • L'Hospitalet de Llobregat, Barecelona, Spanien, 08908
        • Aktiv, ikke rekrutterende
        • Institut Català d´Oncología (ICO)-H. Durán i Reynals
    • Castellon
      • Castellon, Castellon, Spanien, 12002
        • Aktiv, ikke rekrutterende
        • Consorcio Hospitalario Provincial de Castellon
    • Madrid
      • Pozuelo de Alarcón, Madrid, Spanien, 28223
        • Rekruttering
        • Hospital Quironsalud Madrid
    • Kyǒnggi-do
      • Seongnam, Kyǒnggi-do, Sydkorea, 13620
        • Rekruttering
        • Seoul National University Bundang Hospital
    • Seoul-teukbyeolsi [seoul]
      • Seoul, Seoul-teukbyeolsi [seoul], Sydkorea, 03080
        • Aktiv, ikke rekrutterende
        • Seoul National University Hospital
      • Seoul, Seoul-teukbyeolsi [seoul], Sydkorea, 07985
        • Aktiv, ikke rekrutterende
        • Ewha Womans University Mokdong Hospital
      • Seoul, Seoul-teukbyeolsi [seoul], Sydkorea, 03722
        • Aktiv, ikke rekrutterende
        • Severance Hospital, Yonsei University Health System
    • Taejǒn-kwangyǒkshi
      • Daejeon, Taejǒn-kwangyǒkshi, Sydkorea, 35015
        • Aktiv, ikke rekrutterende
        • Chungnam national university hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Part 1 and Part 2 (Closed for enrollment).

Part 3 Key Inclusion Criteria:

  • Histological or cytological diagnosis of castration resistant prostate cancer.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
  • Adequate bone marrow, renal, and liver function

Part 3 Key Exclusion Criteria:

  • Prior irradiation to >25% of the bone marrow.
  • QTcF interval >480 msec at screening.
  • Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
  • Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
  • Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
  • Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
  • Prior enzalutamide within the last 4 weeks
  • DDI SUBSTUDY:
  • history of CHF or evidence of ventricular dysfunction
  • fructose intolerance
  • coadministration of CYP3A4 substrates

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Dose Escalation (Part 1A)

Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels

Oral continuous

Andre navne:
  • EZH2i
Eksperimentel: Dose Escalation (Part 1B)

Participants with FL will receive mevrometostat at escalating dose levels

Oral continuous

Andre navne:
  • EZH2i
Eksperimentel: Dose Escalation (Part 1C)

Participants with mCRPC will receive mevrometostat at escalating dose levels.

Oral continuous

Andre navne:
  • EZH2i
Eksperimentel: Dose Escalation (Part 2A)

Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC.

Oral continuous

Andre navne:
  • EZH2i

Oral continuous

Andre navne:
  • Xtandi
Eksperimentel: Dose Expansion (Part 2B)

Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone.

Oral continuous

Andre navne:
  • EZH2i

Oral continuous

Andre navne:
  • Xtandi
Eksperimentel: Japan Cohort

Participants with CRPC will receive mevrometostat at one or two doses

Oral continuous

Andre navne:
  • EZH2i
Eksperimentel: China cohort

Participants will receive mevrometostat at one or two doses

Oral continuous

Andre navne:
  • EZH2i
Eksperimentel: Dose Expansion (Part 2C)

Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC

Oral continuous

Andre navne:
  • EZH2i

Oral continuous

Andre navne:
  • Xtandi
Eksperimentel: BE Substudy

In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day.

Oral continuous

Andre navne:
  • EZH2i

Oral continuous

Andre navne:
  • Xtandi
Eksperimentel: DDI Substudy

The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day.

Oral continuous

Andre navne:
  • EZH2i

Oral continuous

Andre navne:
  • Xtandi

Oral solution

Andre navne:
  • Sporanox
  • Tolsura
  • Onmel

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
Tidsramme: Baseline up to 90 days

First cycle DLTs will be utilized to determine the MTD

Baseline up to 90 days
Overall safety profile including adverse events
Tidsramme: Baseline up to approximately 2 years

Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03])

Baseline up to approximately 2 years
Preliminary efficacy determination as evaluated by disease specific response criteria
Tidsramme: Through study completion, approximately 2 years past last patient first visit.

Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC.

Through study completion, approximately 2 years past last patient first visit.
Overall safety profile including laboratory abnormalities
Tidsramme: Baseline up to approximately 2 years

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing.

Baseline up to approximately 2 years
Overall safety profile including vital signs
Tidsramme: Baseline up to approximately 2 years

Vital sign changes from baseline including blood pressure, heart rate, ECG changes.

Baseline up to approximately 2 years
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
Tidsramme: Baseline until disease progression or death or through study completion (approx 2 years)

PCWG3

Baseline until disease progression or death or through study completion (approx 2 years)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
Tidsramme: Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.

Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC)

Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
Evaluate overall survival
Tidsramme: Baseline up to approximately 2 years

Median time to death proportion of patients alive at 6 months, 1 year, and 2 years.

Baseline up to approximately 2 years
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
Tidsramme: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Tidsramme: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Area Under the Curve (AUC)
Tidsramme: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
Tidsramme: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
Tidsramme: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
Tidsramme: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Singe dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Evaluate the impact of mevrometostat on patient reported outcomes.
Tidsramme: At specific time-points from Cycle 1 Day 1 to End of Treatment visit.

Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P.

At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
Tidsramme: At specific time points from Cycle1 Day 1 to end of treatment

Questionnaire customized from PRO-CTCAE.

At specific time points from Cycle1 Day 1 to end of treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. april 2018

Primær færdiggørelse (Anslået)

20. april 2028

Studieafslutning (Anslået)

7. juli 2029

Datoer for studieregistrering

Først indsendt

12. februar 2018

Først indsendt, der opfyldte QC-kriterier

2. marts 2018

Først opslået (Faktiske)

9. marts 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

15. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner